VRTX Earnings
Latest Revenue3.3B
Latest Net Income1.1B
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $4.34 | 3.3B | 1.1B | +12.5% | +8.0% |
| Q1 2026 | $4.06 | 3.0B | 1.0B | +7.8% | +61.1% |
| Q4 2025 | $4.70 | 3.2B | 1.2B | +9.5% | +32.4% |
| Q3 2025 | $4.24 | 3.1B | 1.1B | +11.0% | +4.7% |
| Q2 2025 | $4.02 | 3.0B | 1.0B | +12.1% | +128.9% |
| Q1 2025 | $2.52 | 2.8B | 646.3M | +3.0% | -40.8% |
| Q4 2024 | $3.55 | 2.9B | 913.0M | +15.7% | -5.6% |
| Q3 2024 | $4.05 | 2.8B | 1.0B | +11.6% | +1.0% |
| Q2 2024 | -$13.92 | 2.6B | -3593600000 | — | — |
| Q1 2024 | $4.26 | 2.7B | 1.1B | — | — |
| Q4 2023 | $3.76 | 2.5B | 968.8M | — | — |
| Q3 2023 | $4.01 | 2.5B | 1.0B | — | — |
Vertex Pharmaceuticals (VRTX) — Earnings